Stocks Listing
RCUS

Arcus Biosciences, Inc.

Share
RCUS
$26.20 0.15%Last Updated Oct 03 2022 07:56 PM
1D Low / 1D High
Low:$25.65
High:$27.24
1D
0.15%
5D
-
30D
-
BulletPurple
Market Cap
$1,890,592,000
0.15 %
1.9 B
BulletBlue
Volume 1D
323,079
-
323.1 K
BulletOrange
Circulating Supply
72,160,000 RCUS
72.2 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Closed
NYQ
New York Stock Exchange
USA
Opens in
17 hours, 18 minutes
Working Hours
Mon-Fri, 01:30 PM - 08:00 PM
Timezone
GMT+0